{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T02:23:43Z","timestamp":1790562223555,"version":"4.1.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","brachyjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Brachytherapy"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.brachy.2024.09.007","type":"journal-article","created":{"date-parts":[[2024,10,19]],"date-time":"2024-10-19T19:02:01Z","timestamp":1729364521000},"page":"36-44","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Salvage interstitial brachytherapy for treatment of recurrent endometrial cancers in the vagina: Seven-year single institution experience and review of second recurrence patterns"],"prefix":"10.1016","volume":"24","author":[{"given":"Marissa","family":"Sherwood","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toni","family":"Barnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanbo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3562-5890","authenticated-orcid":false,"given":"Amandeep","family":"Taggar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moti","family":"Paudel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aishah","family":"Alqaderi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.brachy.2024.09.007_bib0001","unstructured":"National Cancer Institute - Surveillance EaERP. Cancer stats facts - uterine cancer 2023 [Available at: https:\/\/seer.cancer.gov\/statfacts\/html\/corp.html. Accessed March 19, 2024."},{"key":"10.1016\/j.brachy.2024.09.007_bib0002","unstructured":"Canadian Cancer Society. Canadian cancer statistics 2023: canadian cancer society; 2023 [Available at: https:\/\/cancer.ca\/en\/research\/cancer-statistics. Accessed March 19, 2024."},{"key":"10.1016\/j.brachy.2024.09.007_bib0003","unstructured":"NCCN. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) - uterine neoplasms version 1.2024. 2023. Accessed March 19, 2024."},{"key":"10.1016\/j.brachy.2024.09.007_bib0004","doi-asserted-by":"crossref","first-page":"e631","DOI":"10.1016\/j.ijrobp.2011.04.013","article-title":"Fifteen-year radiotherapy outcomes of the randomized PORTEC-1 trial for endometrial carcinoma","volume":"81","author":"Creutzberg","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2024.09.007_bib0005","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/S1470-2045(19)30395-X","article-title":"Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial","volume":"20","author":"de Boer","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.brachy.2024.09.007_bib0006","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.brachy.2011.06.008","article-title":"American Brachytherapy Society consensus guidelines for interstitial brachytherapy for vaginal cancer","volume":"11","author":"Beriwal","year":"2012","journal-title":"Brachytherapy."},{"key":"10.1016\/j.brachy.2024.09.007_bib0007","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.brachy.2017.07.012","article-title":"American Brachytherapy Society recurrent carcinoma of the endometrium task force patterns of care and review of the literature","volume":"16","author":"Kamrava","year":"2017","journal-title":"Brachytherapy."},{"key":"10.1016\/j.brachy.2024.09.007_bib0008","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.brachy.2016.06.010","article-title":"High-dose-rate interstitial brachytherapy for the treatment of high-volume locally recurrent endometrial carcinoma","volume":"15","author":"Huang","year":"2016","journal-title":"Brachytherapy"},{"key":"10.1016\/j.brachy.2024.09.007_bib0009","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.brachy.2021.12.010","article-title":"Clinical outcomes and dosimetric predictors of toxicity for re-irradiation of vaginal recurrence of endometrial cancer","volume":"21","author":"Lee","year":"2022","journal-title":"Brachytherapy"},{"key":"10.1016\/j.brachy.2024.09.007_bib0010","unstructured":"US Department of Health and Human Services. National Cancer Institute DCTD. Common terminology criteria for adverse events (CTCAE) version 5.0, 2017."},{"key":"10.1016\/j.brachy.2024.09.007_bib0011","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.brachy.2019.05.007","article-title":"MRI-based interstitial brachytherapy for vaginal tumors: a multi-institutional study on practice patterns, contouring, and consensus definitions of target volumes","volume":"18","author":"Leung","year":"2019","journal-title":"Brachytherapy"},{"key":"10.1016\/j.brachy.2024.09.007_bib0012","doi-asserted-by":"crossref","first-page":"173","DOI":"10.5114\/jcb.2016.61062","article-title":"Institutional experience using interstitial brachytherapy for the treatment of primary and recurrent pelvic malignancies","volume":"8","author":"Aridgides","year":"2016","journal-title":"J Contemp Brachytherapy"},{"issue":"6","key":"10.1016\/j.brachy.2024.09.007_bib0013","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.3390\/cancers13061226","article-title":"Image-guided brachytherapy for salvage reirradiation: a systematic review","volume":"13","author":"Bockel","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.brachy.2024.09.007_bib0014","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.brachy.2014.01.008","article-title":"Phase II trial of image-based high-dose-rate interstitial brachytherapy for previously irradiated gynecologic cancer","volume":"13","author":"Mart\u00ednez-Monge","year":"2014","journal-title":"Brachytherapy"},{"key":"10.1016\/j.brachy.2024.09.007_bib0015","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/j.brachy.2017.07.002","article-title":"Salvage high-dose-rate brachytherapy and external beam radiotherapy for isolated vaginal recurrences of endometrial cancer with no prior adjuvant therapy","volume":"16","author":"Chapman","year":"2017","journal-title":"Brachytherapy"},{"key":"10.1016\/j.brachy.2024.09.007_bib0016","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.brachy.2016.08.005","article-title":"Salvage high-dose-rate brachytherapy for isolated vaginal recurrence of endometrial cancer","volume":"15","author":"Baek","year":"2016","journal-title":"Brachytherapy"},{"key":"10.1016\/j.brachy.2024.09.007_bib0017","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.clon.2019.07.015","article-title":"Salvage re-irradiation with single-modality interstitial brachytherapy for the treatment of recurrent gynaecological tumours in the pelvis: a multi-institutional study","volume":"32","author":"Raziee","year":"2020","journal-title":"Clinical Oncology"},{"key":"10.1016\/j.brachy.2024.09.007_bib0018","first-page":"241","article-title":"Treatment of vaginal recurrences in endometrial carcinoma by high-dose-rate brachytherapy","volume":"33","author":"Sorbe","year":"2013","journal-title":"Anticancer Res"},{"key":"10.1016\/j.brachy.2024.09.007_bib0019","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1006\/gyno.1999.5487","article-title":"Interstitial brachytherapy for vaginal recurrences of endometrial carcinoma","volume":"74","author":"Tewari","year":"1999","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.brachy.2024.09.007_bib0020","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/j.brachy.2017.07.007","article-title":"MR- versus CT-based high-dose-rate interstitial brachytherapy for vaginal recurrence of endometrial cancer","volume":"16","author":"Kamran","year":"2017","journal-title":"Brachytherapy"},{"key":"10.1016\/j.brachy.2024.09.007_bib0021","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ijrobp.2006.04.037","article-title":"Magnetic resonance-guided interstitial therapy for vaginal recurrence of endometrial cancer","volume":"66","author":"Viswanathan","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2024.09.007_bib0022","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.ijrobp.2022.09.072","article-title":"GEC-ESTRO (ACROP)-ABS-CBG consensus brachytherapy target definition guidelines for recurrent endometrial and cervical tumors in the vagina","volume":"115","author":"Kamrava","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"10.1016\/j.brachy.2024.09.007_bib0023","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.3390\/cancers13061478","article-title":"The TCGA molecular classification of endometrial cancer and its possible impact on adjuvant treatment decisions","volume":"13","author":"Alexa","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"19","key":"10.1016\/j.brachy.2024.09.007_bib0024","doi-asserted-by":"crossref","first-page":"11684","DOI":"10.3390\/ijms231911684","article-title":"TCGA molecular prognostic groups of endometrial carcinoma: current knowledge and future perspectives","volume":"23","author":"Arciuolo","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.brachy.2024.09.007_bib0025","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1200\/JCO.20.00549","article-title":"Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: impact on prognosis and benefit from adjuvant therapy","volume":"38","author":"Le\u00f3n-Castillo","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.brachy.2024.09.007_bib0026","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/0360-3016(88)90110-1","article-title":"Vaginal recurrences of endometrial carcinoma: the prognostic value of staging by a primary vaginal carcinoma system","volume":"15","author":"Curran","year":"1988","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2024.09.007_bib0027","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1056\/NEJMoa2108330","article-title":"Lenvatinib plus pembrolizumab for advanced endometrial cancer","volume":"386","author":"Makker","year":"2022","journal-title":"N Engl J Med"}],"container-title":["Brachytherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538472124004008?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538472124004008?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T12:13:54Z","timestamp":1737634434000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538472124004008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S1538472124004008"],"URL":"https:\/\/doi.org\/10.1016\/j.brachy.2024.09.007","relation":{},"ISSN":["1538-4721"],"issn-type":[{"value":"1538-4721","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Salvage interstitial brachytherapy for treatment of recurrent endometrial cancers in the vagina: Seven-year single institution experience and review of second recurrence patterns","name":"articletitle","label":"Article Title"},{"value":"Brachytherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.brachy.2024.09.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc. on behalf of American Brachytherapy Society.","name":"copyright","label":"Copyright"}]}}